Journal article
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
H Butzkueven, T Spelman, D Horakova, S Hughes, C Solaro, G Izquierdo, E Kubala Havrdová, F Grand'Maison, A Prat, M Girard, R Hupperts, M Onofrj, A Lugaresi, B Taylor, G Giovannoni, L Kappos, SL Hauser, X Montalban, L Craveiro, R Freitas Show all
European Journal of Neurology | Published : 2022
DOI: 10.1111/ene.14824
Open access
Abstract
Background and purpose: Reaching Expanded Disability Status Scale (EDSS) ≥7.0 represents the requirement for a wheelchair. Here we (i) assess the effect of ocrelizumab on time to EDSS ≥7.0 over the ORATORIO (NCT01194570) double-blind and extended controlled periods (DBP+ECP), (ii) quantify likely long-term benefits by extrapolating results, and (iii) assess the plausibility of extrapolations using an independent real-world cohort (MSBase registry; ACTRN12605000455662). Methods: Post hoc analyses assessing time to 24-week confirmed EDSS ≥7.0 in two cohorts of patients with primary progressive multiple sclerosis (baseline EDSS 3.0–6.5) were investigated in ORATORIO and MSBase. Results: In the ..
View full abstractGrants
Funding Acknowledgements
This work was financially supported by F. Hoffmann-La Roche Ltd., Basel, Switzerland for the study and publication of the article.